Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Why the weakness today?

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Feb 11, 2021 2:47pm

146 Views

Post# 32543040

RE:RE:RE:Why the weakness today?

The markets are down today and some profit taking, We are going into the long weekend and not like news .. and three weeks yoll
rmd of the month. It will pick up pace next week ..IMO

quote=Alex1967]FDA link
https://www.cdc.gov/stroke/facts.htm#:~:text=Every%20year%2C%20more%20than%20795%2C000%20people%20in%20the,blood%20flow%20to%20the%20brain%20is%20blocked.%202[/quote]

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs